Bliss GVS Pharma Ltd
Incorporated in 1984, Bliss GVS Pharma Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical formulations in the form of suppositories, pessaries, capsules, tablets, and syrups.
- Market Cap ₹ 767 Cr.
- Current Price ₹ 73.6
- High / Low ₹ 96.9 / 66.1
- Stock P/E 8.80
- Book Value ₹ 82.0
- Dividend Yield 0.68 %
- ROCE 14.2 %
- ROE 3.48 %
- Face Value ₹ 1.00
Pros
- Stock is trading at 0.90 times its book value
Cons
- The company has delivered a poor sales growth of -1.31% over past five years.
- Promoter holding is low: 34.5%
- Company has a low return on equity of 8.83% over last 3 years.
- Company has high debtors of 192 days.
- Promoter holding has decreased over last 3 years: -7.14%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
219 | 267 | 397 | 345 | 407 | 547 | 798 | 815 | 899 | 689 | 577 | 747 | 734 | |
161 | 196 | 285 | 273 | 304 | 391 | 596 | 618 | 739 | 566 | 471 | 629 | 603 | |
Operating Profit | 58 | 71 | 111 | 71 | 103 | 156 | 203 | 197 | 160 | 123 | 107 | 118 | 131 |
OPM % | 27% | 27% | 28% | 21% | 25% | 29% | 25% | 24% | 18% | 18% | 18% | 16% | 18% |
3 | 16 | 14 | 28 | 20 | 24 | 12 | -8 | 35 | 26 | 20 | -42 | 27 | |
Interest | 2 | 4 | 10 | 18 | 16 | 19 | 20 | 23 | 4 | 8 | 6 | 5 | 7 |
Depreciation | 5 | 4 | 6 | 11 | 11 | 13 | 20 | 21 | 9 | 13 | 17 | 17 | 18 |
Profit before tax | 53 | 79 | 109 | 71 | 96 | 148 | 175 | 145 | 182 | 129 | 104 | 54 | 133 |
Tax % | 23% | 34% | 46% | 42% | 36% | 32% | 36% | 39% | 30% | 26% | 29% | 57% | |
Net Profit | 41 | 53 | 60 | 41 | 61 | 100 | 113 | 89 | 127 | 95 | 74 | 23 | 97 |
EPS in Rs | 3.94 | 5.09 | 5.60 | 3.97 | 5.81 | 8.00 | 7.95 | 5.70 | 11.99 | 9.43 | 6.64 | 1.45 | 8.38 |
Dividend Payout % | 15% | 15% | 12% | 13% | 12% | 6% | 8% | 18% | 8% | 5% | 8% | 34% |
Compounded Sales Growth | |
---|---|
10 Years: | 11% |
5 Years: | -1% |
3 Years: | -6% |
TTM: | 3% |
Compounded Profit Growth | |
---|---|
10 Years: | -6% |
5 Years: | -19% |
3 Years: | -39% |
TTM: | 35% |
Stock Price CAGR | |
---|---|
10 Years: | 7% |
5 Years: | -17% |
3 Years: | -19% |
1 Year: | -23% |
Return on Equity | |
---|---|
10 Years: | 14% |
5 Years: | 12% |
3 Years: | 9% |
Last Year: | 3% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Sep 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | |
Reserves | 156 | 200 | 248 | 277 | 327 | 402 | 476 | 526 | 636 | 725 | 798 | 808 | 843 |
8 | 45 | 148 | 173 | 160 | 132 | 225 | 118 | 102 | 126 | 122 | 109 | 103 | |
39 | 54 | 165 | 123 | 166 | 218 | 311 | 206 | 157 | 168 | 147 | 181 | 144 | |
Total Liabilities | 213 | 310 | 571 | 583 | 662 | 762 | 1,023 | 860 | 905 | 1,030 | 1,077 | 1,109 | 1,101 |
20 | 40 | 168 | 213 | 234 | 225 | 305 | 143 | 146 | 242 | 234 | 281 | 278 | |
CWIP | 8 | 7 | 1 | 4 | -0 | 9 | 4 | 0 | 47 | -0 | 2 | 22 | 39 |
Investments | -0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 |
186 | 262 | 402 | 365 | 428 | 527 | 714 | 717 | 712 | 788 | 840 | 803 | 781 | |
Total Assets | 213 | 310 | 571 | 583 | 662 | 762 | 1,023 | 860 | 905 | 1,030 | 1,077 | 1,109 | 1,101 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
36 | 6 | 41 | 38 | 113 | 289 | 18 | 40 | 47 | 64 | 135 | ||
-22 | -124 | -11 | -29 | -50 | -249 | 48 | -79 | -40 | -45 | -103 | ||
26 | 110 | -8 | -42 | -40 | -10 | -76 | 17 | -6 | -21 | -24 | ||
Net Cash Flow | 40 | -8 | 22 | -34 | 23 | 30 | -10 | -22 | 0 | -2 | 9 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 200 | 176 | 225 | 228 | 222 | 201 | 116 | 134 | 187 | 290 | 293 | 192 |
Inventory Days | 33 | 29 | 58 | 70 | 69 | 55 | 50 | 55 | 46 | 64 | 110 | 116 |
Days Payable | 90 | 95 | 212 | 176 | 165 | 153 | 100 | 55 | 47 | 75 | 82 | 86 |
Cash Conversion Cycle | 143 | 111 | 71 | 121 | 126 | 102 | 67 | 134 | 186 | 279 | 321 | 221 |
Working Capital Days | 165 | 135 | 130 | 146 | 160 | 125 | 76 | 182 | 180 | 269 | 319 | 219 |
ROCE % | 39% | 36% | 20% | 24% | 32% | 31% | 29% | 27% | 19% | 12% | 14% |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 2 Feb
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
30 Jan - Copies of newspaper advertisement of Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2022 published in 'The Economic …
- Board Meeting Outcome For Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Nine Months Ended December 31, 2022 24 Jan
- Board Meeting Intimation for Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Nine Months Ended December 31, 2022 17 Jan
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
12 Jan - Certificate received from Universal Capital Securities Private Limited, Registrar and Share Transfer Agent of the Company under Regulation 74(5) of the SEBI (Depositories and Participants) …
Annual reports
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Portfolio:
a) Pharma Products:[1]
Capsules, Creams/Gels/Ointments, Dry Powder for Injection and for Oral Suspension, Eye/Ear Drops, Effervescent tablets, Lotions, Injections, Liquid Preparations, Lozenges, Nasal Solutions, Oral Solids, Parenteral, etc.
b) Other Healthcare Products:[2]
Balm, Cream, Lotion, OTC products, Petroleum Jelly, Powder, Roll On
c) Therapeutics:[3]
Analgesic, Antacid, Anti-malarial, Anti-fungal, Anti-bacterial, Anti-biotic, Anti-inflammatory, Anti-diarrheic, anti-diabetic, etc.